Skandinaviska Enskilda Banken AB publ Sells 20,100 Shares of DaVita Inc. (NYSE:DVA)

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 43.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 26,306 shares of the company’s stock after selling 20,100 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in DaVita were worth $3,645,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of DaVita by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after acquiring an additional 145,711 shares during the last quarter. Gates Capital Management Inc. increased its holdings in shares of DaVita by 3.1% during the 4th quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after purchasing an additional 27,660 shares during the period. 8 Knots Management LLC acquired a new position in shares of DaVita during the fourth quarter valued at about $89,504,000. Allianz Asset Management GmbH lifted its stake in shares of DaVita by 63.9% in the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after buying an additional 213,992 shares during the period. Finally, Doma Perpetual Capital Management LLC acquired a new stake in DaVita during the fourth quarter worth about $53,076,000. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

DVA has been the subject of a number of research reports. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Truist Financial upped their target price on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. UBS Group increased their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen upped their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Bank of America increased their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average price target of $157.00.

Insider Activity

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares in the company, valued at approximately $141,219,407.87. The disclosure for this sale can be found here. In the last quarter, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by insiders.

DaVita Stock Up 0.5 %

Shares of NYSE:DVA opened at $164.00 on Monday. DaVita Inc. has a 12 month low of $71.51 and a 12 month high of $166.04. The company’s 50-day moving average price is $147.64 and its two-hundred day moving average price is $141.23. The firm has a market cap of $14.38 billion, a P/E ratio of 18.64, a P/E/G ratio of 0.95 and a beta of 0.87. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $2.08 EPS. As a group, research analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.